SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is seeing significant volatility following a definitive agreement to acquire several Boeing subsidiaries, a move the community views as a major strategic shift toward a defense-focused autonomy platform. While bulls are energized by the Boeing collaboration and perceived institutional validation, bears remain skeptical, citing continued concerns over share dilution and the lack of a fully transitioned piloted aircraft.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is trending as investors weigh a major infrastructure funding deal involving Wall Street giants against rising geopolitical tensions and concerns over capital-intensive AI spending. The community is actively debating the stock's future direction, with bullish sentiment driven by strong demand signals from chip supply chain partners and bearish traders pointing toward market manipulation and macroeconomic risks.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera is currently at the center of investor attention following its strategic collaboration with Vertex Pharmaceuticals, a move that reinforces its platform's credibility alongside the recent Jazz Pharmaceuticals partnership. While short-term price action remains volatile due to heavy short interest and speculation surrounding upcoming Phase 2 data for its ABCL635 program, the community is actively debating the company's long-term potential as a standalone drug developer versus its established role as a discovery service provider.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust (SLV) is seeing intense community debate as traders weigh its role as a hedge against fiat currency devaluation and mounting national debt. While many investors are maintaining long-term bullish positions on silvers industrial potential and macro resilience, others are cautious of historical price volatility and active short-term speculative selling.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is trending due to its role as a key beneficiary of accelerating AI adoption and cloud observability demand, as evidenced by consistent earnings beats and raised guidance. Investors are actively discussing the stock's strong relative strength and institutional accumulation while debating the sustainability of its high valuation amidst a broader sector rotation.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is in the spotlight as investors anticipate topline Phase 3 data from the IZAR-1 trial for psoriatic arthritis, a critical binary event that will determine the drug's competitive standing. The community remains divided between extreme optimism regarding a potential best-in-class profile and frustration over communication delays regarding the trial's readout timeline.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is experiencing extreme volatility and heavy sell-side pressure following a disappointing quarterly report that included weakened growth projections and a series of analyst downgrades. Community discourse is heavily divided between frustrated long-term shareholders calling for management changes and contrarian investors viewing the recent sharp decline as a potential value opportunity driven by overblown panic.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is seeing active community discussion as investors weigh its cybersecurity growth against high insider selling and lofty valuations. The stock remains a focus for traders tracking potential momentum breakouts, with the community closely analyzing its positioning in the AI-driven data security market as a key differentiator from other software peers.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick Mining is trending as investors react to a significant quarterly earnings beat, a new three billion dollar share buyback program, and the strategic push toward a North American gold asset IPO. Community sentiment remains mixed, with some traders optimistic about the company's long-term gold and copper growth potential, while others express concerns over execution risks, rising mining costs, and recent management communication.

Coherent Corp. engages in the development, refinement, manufacturing, and marketing of engineered materials, opto-electronic components and devices, and lasers for use in the industrial, communications, electronics, and instrumentation markets. It operates through the following segments: Networking, Materials, and Lasers. The Networking segment leverages compound semiconductor technology platforms and deep knowledge of end-user applications. The Materials segment markets engineered materials and optoelectronic devices. The Lasers segment serves industrial customers in semiconductor capital equipment, display capital equipment, precision manufacturing, and aerospace and defense, as well as instrumentation customers in life sciences and scientific research. The company was founded by Carl J. Johnson in 1971 and is headquartered in Saxonburg, PA.

Coherent Corp

Coherent Corp is trending as investors aggressively buy the dip following a sharp sector-wide rotation and volatility in optical networking stocks. The community remains focused on the company's role as a critical AI infrastructure supplier, with significant interest driven by strategic NVIDIA partnerships and ongoing supply chain bottlenecks that keep high-speed optical hardware in high demand.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Kymera Therapeutics Poised for a Breakthrough With KT-621?

Kymera Therapeutics advances KT-621 enrollment ahead of schedule, bringing pivotal atopic dermatitis data closer as it expands its protein degrader pipeline.

Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum

RHHBY posts 6% constant-currency sales growth in the first half of 2026 as strong demand for key drugs offsets legacy declines, while FDA pipeline progress supports momentum.

RHHBY's Gazyva Gets FDA Priority Review for Label Expansion 

Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.

Company News for July 13, 2026

Companies In The Article Are:WDFC,DAL,NRIX and FCX

Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates

Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -10.96% and -36.76%, respectively, for the quarter ended May 2026. Do the numbers hold clues to what lies ahead for the stock?

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire SAN FRANCISCO, July 6, 2026 Issued on...

Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug 

RHHBY announces positive phase III Krascendo 1 results for divarasib in KRAS G12C NSCLC, showing PFS and OS gains versus approved inhibitors.

Earnings Preview: Nurix Therapeutics, Inc. (NRIX) Q2 Earnings Expected to Decline

Nurix Therapeutics (NRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts Believe Nurix Therapeutics (NRIX) Could Rally 29.23%: Here's is How to Trade

The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 29.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Roche Gets FDA Priority Review for Enspryng in Thyroid Eye Disease

Roche won FDA priority review for Enspryng in thyroid eye disease, with a decision date in October and phase III data backing the filing.

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in Brisbane, CA.

Nurix Therapeutics Inc

NRIX Stock Surges Nearly 70% Premarket Today – Roche And Nurix’s Blood Cancer Drug Collaboration Can Tap A $41B Market

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$25.70
Prev Close	$25.53
Open	$25.21
Dividend Yield	0.00%
50-Day Moving Average	$21.14
Beta	1.62
Avg. Volume	1.16M
PE Ratio	-7.41

52-Week High	$25.89
52-Week Low	$8.20
Market Capitalization	$2.65B
EPS (Annual)	-$3.05
Price to Book	6.58
Revenue Per Employee	$264,921.14

Feed

News

Sentiment

Earnings

Fundamentals

Info